STEATOSIS & PHOSPHOLIPIDOSIS
IVTD’s patented human skin stem cell-derived hepatic cell model (hSKP-HPC or HepaSTARs) provides a sensitive and accurate assay for toxicity screening of novel drug candidates and the detection of drug-induced steatosis, phospholipidosis and acute liver failure, and has been tested using compounds with known toxicity, including sodium valproate and paracetamol. The hSKP-HPC model compares favourably with human hepatocytes, HepG2 and HepaRG™ cells in assessing hepatotoxicty.
- Hepatic cells derived from human skin progenitors show a typical phospholipidotic response upon exposure to amiodarone (2018)
- Toxicogenomics-based prediction of acetaminophen-induced liver injury using human hepatic cell systems (2017)
- In vitro assessment of drug-induced liver steatosis based on human dermal stem cell-derived hepatic cells (2016)
- Human skin-derived stem cells as a novel cell source for in vitro hepatotoxicity screening of pharmaceuticals (2014)
led by Tamara Vanhaecke
miniaturisation of DILI prediction in hSKP-HPC model towards high-throughput drug screening
Mechanistic study of cholestatic liver injury using adverse outcome pathways as the basis for improved in vitro detection of liver toxicity.
- Industrial, Biocide, and Cosmetic Chemical Inducers of Cholestasis (2019)
- Cholestatic liver injury induced by food additives, dietary supplements and parenteral nutrition (2020)
- Omics-based responses induced by bosentan in human hepatoma HepaRG cell cultures (2018).
led by Mathieu Vinken
Development of a primary hepatocyte spheroid culture system for the detection of chemical-induced cholestatic liver injury
- The role of connexins, pannexins, and their channels, in cholestasis
- Characterization of new mechanisms of cholestasis as the basis for animal-free prediction of drug-induced liver injury